Clinician's Pocket Drug Reference 2015
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Download This PDF File
Chimica Analitica ANA-KN-01 Functionalized carbon nanostructures and metal nanoparticles: from effective charge propagation to enhancement of electrocatalytic, photoelectrocatalytic and bioelectrocatalytic properties Pawel J. Kulesza Department of Chemistry, University of Warsaw, Pasteura 1, PL-02-093 Warsaw, Poland * [email protected] Of particular interest to the preparation of advanced materials is synthesis and characterization of carbon nanostructures (e.g. nanotubes) and noble metal nanoparticles, their stabilization (e.g. through self-assembly), as well as organization into two-dimensional arrays and controlled fabrication (e.g. through the sequential attraction) into three-dimensional network films. They can form nanosized materials with well-defined composition, structure and thickness. The interfaces can be also highly functionalized, and they can exhibit specific catalytic or unique electronic, charge storage, optical and sensing properties. We explore here the ability of inorganic structures to stabilize and derivatize metal and carbon nanostructures. Among inorganic systems, polyoxometallates of molybdenum and tungsten are attractive since they can not only adsorb irreversibly on solid surfaces but also exhibit reversible stepwise multielectron transfer reactions. The concept of the layer-by-layer formation of hybrid (organic-inorganic) assemblies composed of anionic polyoxometallate-protected carbon nanotubes (or metal nanoparticles) and ultra-thin films of positively charged conducting polymers (e.g. such as polyaniline or PEDOT) will be described and discussed here. The resulting novel composite materials have been fabricated as thin or moderately thick (µm level) films on electrode surfaces. As evidenced from STM and scanning electron microscopy, their morphology is still granular but the structure is fairly dense. Further, they are characterized by fast dynamics of charge propagation. -
University of Birmingham Uterotonic Agents for Preventing Postpartum
University of Birmingham Uterotonic agents for preventing postpartum haemorrhage Gallos, Ioannis D; Williams, Helen M; Price, Malcolm J; Merriel, Abi; Gee, Harold; Lissauer, David; Moorthy, Vidhya; Tobias, Aurelio; Deeks, Jonathan J; Widmer, Mariana; Tunçalp, Özge; Gülmezoglu, Ahmet Metin; Hofmeyr, G Justus; Coomarasamy, Arri DOI: 10.1002/14651858.CD011689.pub2 License: None: All rights reserved Document Version Publisher's PDF, also known as Version of record Citation for published version (Harvard): Gallos, ID, Williams, HM, Price, MJ, Merriel, A, Gee, H, Lissauer, D, Moorthy, V, Tobias, A, Deeks, JJ, Widmer, M, Tunçalp, Ö, Gülmezoglu, AM, Hofmeyr, GJ & Coomarasamy, A 2018, 'Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis', Cochrane Database of Systematic Reviews, vol. 2018, no. 4, CD011689. https://doi.org/10.1002/14651858.CD011689.pub2 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked for eligibility:17/05/2018 Gallos ID, Williams HM, Price MJ, Merriel A, Gee H, Lissauer D, Moorthy V, Tobias A, Deeks JJ, Widmer M, Tunçalp Ö, Gülmezoglu AM, Hofmeyr GJ, Coomarasamy A. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD011689. DOI: 10.1002/14651858.CD011689.pub2. General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. -
Testing Kits for Kinesiologists & Natural Therapists
Testing Kits for Kinesiologists & Natural Therapists The kits come in easy seal bags and boxes are available separately for storage if required (see below). Postage will range from $7.00 to $13.00 ($12 to $26 for Express). The prices of these kits may change from time to time. Please check before or when ordering as to any prices changes. Individual vials may be purchased from kits for $17 each (or $13 each for 7 or more). Other single vials & update vials - see pages back of manual This manual is available at $29.00 plus $7.00 postage. With kit purchases it is available at a basic price of $19.00. After an initial purchase, any updated or later editions can be purchased at $15.00 plus $7.00 postage. Testing Kit Boxes & Empty Vials: Test Kit Box for 50 Vials (plastic box - vials upright): $13.00 or $10.00 with kits Test Kit Box for 100 Vials (plastic box - vials upright): $17.00 or $14.00 with Kits Test Kit Box for 72 vials (flat cardboard box with foam inlay – vials lay flat): $42 or $35 with kits Empty Vials for Liquids: 8 x 40 mm glass vial with plastic top: $6.00 per 10 vials or $52.00 per 100 pack. Empty Vials for Solids: 10 x 40mm glass vial with plastic top: $8.00 per 10 vials or $69.00 per 100 pack Pathology & Histology Testing Kits A Range of Kinesiological Testing Kits for Anatomy & Pathologies of the Body Organs & Systems (contents lists included in this manual) see contents page 3 Flower Essences We supply a variety of Flower Essences, and other types of Essences, plus accessories. -
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems. -
Malaysian Statistics on Medicines 2009 & 2010
MALAYSIAN STATISTICS ON MEDICINES 2009 & 2010 Edited by: Siti Fauziah A., Kamarudin A., Nik Nor Aklima N.O. With contributions from: Faridah Aryani MY., Fatimah AR., Sivasampu S., Rosliza L., Rosaida M.S., Kiew K.K., Tee H.P., Ooi B.P., Ooi E.T., Ghan S.L., Sugendiren S., Ang S.Y., Muhammad Radzi A.H. , Masni M., Muhammad Yazid J., Nurkhodrulnada M.L., Letchumanan G.R.R., Fuziah M.Z., Yong S.L., Mohamed Noor R., Daphne G., Chang K.M., Tan S.M., Sinari S., Lim Y.S., Tan H.J., Goh A.S., Wong S.P., Fong AYY., Zoriah A, Omar I., Amin AN., Lim CTY, Feisul Idzwan M., Azahari R., Khoo E.M., Bavanandan S., Sani Y., Wan Azman W.A., Yusoff M.R., Kasim S., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Suganthi T., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I, Wan Hamilton W.H., Zaridah S., Maisarah A.H., Rohan Malek J., Selvalingam S., Lei C.M., Hazimah H., Zanariah H., Hong Y.H.J., Chan Y.Y., Lin S.N., Sim L.H., Leong K.N., Norhayati N.H.S, Sameerah S.A.R, Rahela A.K., Yuzlina M.Y., Hafizah ZA ., Myat SK., Wan Nazuha W.R, Lim YS,Wong H.S., Rosnawati Y., Ong S.G., Mohd. Shahrir M.S., Hussein H., Mary S.C., Marzida M., Choo Y. M., Nadia A.R., Sapiah S., Mohd. Sufian A., Tan R.Y.L., Norsima Nazifah S., Nurul Faezah M.Y., Raymond A.A., Md. -
Traditional Preparations Used As Uterotonics in Sub‐
International Journal of Gynecology and Obstetrics 120 (2013) 16–22 Contents lists available at SciVerse ScienceDirect International Journal of Gynecology and Obstetrics journal homepage: www.elsevier.com/locate/ijgo REVIEW ARTICLE Traditional preparations used as uterotonics in Sub-Saharan Africa and their pharmacologic effects Vandana Tripathi a,⁎, Cynthia Stanton a, Frank W.J. Anderson b a Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA b Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA article info abstract Article history: Background: Little is known about the use of traditional preparations for uterotonic effects at or near delivery Received 17 March 2012 in Sub-Saharan Africa. Objective: To describe (1) use of traditional preparations in Sub-Saharan Africa Received in revised form 25 June 2012 intended to have uterotonic effects at or near birth; and (2) results of pharmacologic investigations of the Accepted 23 August 2012 uterotonic properties of such preparations. Search strategy: Structured review of 13 databases. Selection criteria: Articles describing use of traditional preparations in Sub-Saharan Africa with primary data, published Keywords: in English between January 1, 1980 and June 30, 2010. Data collection and analysis: Full-text review using Labor augmentation standard spreadsheet templates. Main results: Objective 1 analysis identified 208 plant species used for Pharmacologic effects Plant species uterotonic effects at or near delivery. The most common use was labor induction/augmentation (n=185). Postpartum hemorrhage Other uses were to expel the placenta, shorten the third stage of labor, manage retained placenta (n=61), Retained placenta and prevent/manage postpartum hemorrhage (n=20). -
Second Generation Antiarrhythmic Agents: Have We Reached Antiarrhythmic Nirvana?
JACC Vol. 9. NO.2 459 February 1987:459-63 EDITORIAL REVIEWS Second Generation Antiarrhythmic Agents: Have We Reached Antiarrhythmic Nirvana? LEONARD N. HOROWITZ, MD, FACC, JOEL MORGANROTH, MD, FACC Philadelphia, Pennsylvania During the first half of the 20th century, antiarrhythmic some cases novel, but because their preapproval evaluations therapy was principally directed toward supraventricular ar followed a more rigorous and circumspect path. More in rhythmia; only relatively recently has therapy of ventricular formation is available to us so we can decide when and how arrhythmias been emphasized. In fact, significant pharma these agents should be employed. cologic treatment of ventricular arrhythmias was minimal Like all antiarrhythmic drugs of the first generation, the until routine use of quinidine and procainamide began in new agents have the potential to provoke or worsen ven the 1950s (1,2). The first generation oral antiarrhythmic tricular arrhythmias. These proarrhythmic effects vary in drugs, quinidine, procainamide and disopyramide, previ incidence and may present a major problem in certain patient ously constituted the principal antiarrhythmic agents for long groups such as those with sustained ventricular tachyar term treatment of ventricular arrhythmias in the United States. rhythrnias, reduced left ventricular function and conduction Compared with modem regulatory standards, the data on disturbances. In common with other antiarrhythmic drugs, which the use of these drugs was based were modest at best the second generation drugs have not been shown to prevent and rudimentary at worst. However, because good clinical sudden death in patients with ventricular ectopic activity. judgment compensates for a multitude of deficiencies, we These factors, along with efficacy and potential toxicity, have been able to provide effective antiarrhythmic therapy must be considered in selecting antiarrhythmic regimens for to many patients with this rather limited pharmacopoeia. -
Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia
A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd. -
Rational Use of Uterotonic Drugs During Labour and Childbirth
Prevention and initial management of postpartum haemorrhage Rational use of uterotonic drugs during labour and childbirth Prevention and treatment of postpartum haemorrhage December 2008 Editors This manual is made possible through sup- Prevention of postpartum hemorrhage port provided to the POPPHI project by the initiative (POPPHI) Office of Health, Infectious Diseases and Nu- trition, Bureau for Global Health, US Agency for International Development, under the POPPHI Contacts terms of Subcontract No. 4-31-U-8954, under Contract No. GHS-I-00-03-00028. POPPHI is For more information or additional copies of implemented by a collaborative effort be- this brochure, please contact: tween PATH, RTI International, and Engen- Deborah Armbruster, Project Director derHealth. PATH 1800 K St., NW, Suite 800 Washington, DC 20006 Tel: 202.822.0033 Susheela M. Engelbrecht Senior Program Officer, PATH PO Box 70241 Overport Durban 4067 Tel: 27.31.2087579, Fax: 27.31.2087549 [email protected] Copyright © 2009, Program for Appropriate Tech- www.pphprevention.org nology in Health (PATH). All rights reserved. The material in this document may be freely used for educational or noncommercial purposes, provided that the material is accompanied by an acknowl- edgement line. Table of contents Preface………………………………………………………………………………………………………………………………………………….3 Supportive care during labour and childbirth…………………………………………………………………………………….4 Rational use of uterotonic drugs during labour………………………………………………………………………………...5 Indications and precautions for augmentation -
Formulation Development Strategies
FORMULATION DEVELOPMENT STRATEGIES FOR ORAL EXTENDED RELEASE DOSAGE FORMS Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.) eingereicht im Fachbereich Biologie, Chemie, Pharmazie der Freien Universität Berlin vorgelegt von ARAYA RAIWA aus Bangkok, Thailand May, 2011 1. Gutachter: Prof. Dr. Roland Bodmeier 2. Gutachter: Prof. Dr. Jürgen Siepmann Disputation am 9.Juni 2011 TO MY FAMILY ACKNOWLEDGEMENTS First and foremost, I wish to express my deepest gratitude to my supervisor, Prof. Dr. Roland Bodmeier for his professional guidance, helpful advices and encouragement. I am very grateful for his scientific and financial support and for providing me such an interesting topic. Furthermore, I am very thankful to him for the opportunity to support his editorial role in the European Journal of Pharmaceutical Sciences. I would like to thank Prof. Dr. Jürgen Siepmann for co-evaluating this thesis. Thanks are extended to Prof. Dr. Herbert Kolodziej, Prof. Dr. Johannes Peter Surmann and Dr. Martin Körber for serving as members of my thesis advisor committee. I am particular thankful to Dr. Andrei Dashevsky, Dr. Nantharat Pearnchob and Dr. Martin Körber for their very useful discussion; Dr. Burkhard Dickenhorst for evaluating parts of this thesis; Mrs. Angelika Schwarz for her assistance with administrative issues; Mr. Andreas Krause, Mrs. Eva Ewest and Mr. Stefan Walter for the prompt and diligent technical support. Sincere thanks are extended to Dr. Ildiko Terebesi, Dr. Burkhard Dickenhorst, Dr. Soravoot Rujivipat and Dr. Samar El-Samaligy for the friendly atmosphere in the lab My special thanks are owing to all members from the Kelchstrasse for their practical advice, enjoyable discussion and kindness throughout the years. -
The Carnivore Code Paul Saladino, M.D
By dag Forssell, Jan 23, 2021 Comments: [email protected] Salicylates as discussed in The Carnivore Code Paul Saladino, M.d. CHAPTER 5: OF UNICORNS AND FAIRY TALES PERHAPSCHAPTER MORE THAN 6: ATTACKany other plant OF molecule,THE OXALATES polyphenols have become associated with the term “superfoods.” They are often dubbed “antioxidants,” and we are told to consume as much of them as possible. It seemsIN THE that FREQUENTLYPREVIOUS every day, two another chapters, ASKEDcompany we talked comes QUESTIONS about out plant with defense a supposedly chemicals magicalthat can supplement, have damaging juice, effectsor powder in ourwith bodiesbold claimsbecause of they’redecreased not inflammationcompatible with and ourlongevity human as operating it touts itssystem. robust In polyphenol this chapter, content. we’re Let’sgoing WHEN I STARTED writing this book, I knew that I would never be able to talkto talkabout about what apolyphenols molecule that actually is produced are and inwhy small we’ve quantities been told as they a waste are address every single possible question that arose from it—that’s what my 2223-2228.Textgoodproduct excerpted for ofus. human Then from metabolismwe’ll thesediscuss but chapters, why occurs I’m in going veryfollowed largeto take amounts bythe text,radically in some tables, next books are for. In an effort to be as comprehensive as possible, 38. Lawrence,contraryplants, andviewpointJ. R.,can Peter,cause that serious theirR., Baxter,purported pain, kidney G. benefits J., stones, Robson, are andnothing other J., moreGraham, issues than when the A. it B., & however,and I am comments including this copied section from to address the manyweb commonlypage listed asked stuffaccumulates of imagination, in our body. -
The Effect of Biological Treatment on Behavior and Communication of Children on the Autistic Spectrum
The Effect of Biological Treatment on Behavior and Communication of Children on the Autistic Spectrum Thesis submitted for the degree of Doctor of Philosophy At the University of Natural Medicine, Santa Fe by Anva Ohn-Bar, M.S. OTR Amirim, Israel May, 2006 Acknowledgements I would like to thank all the people who assisted me in this difficult and complicated project. First and foremost I thank and I appreciate the 9 families of the Autistic and PDD children, who cooperated, received my counseling and took my advice. I know how difficult it was. The beneficial changes most of them brought to their children's lives had an important influence on me. It was frustrating not to get cooperation from the rest of the families, and only because of the ones who did implement the program, I had the energy to continue and believe in what I do. I thank Annette Kahan, PhD. for all her assistance, wise feedback and expert comments. I thank Dr. Adiel Tel-Oren, for his support and useful comments and ideas. I also thank my family, who had to put up with a very busy and tired mother all this time…and especially my son Eshed, who helped me so much with the computer, the charts and all the technical part of writing… And last but not least, my husband Ohn, who supported me throughout the process. Without his love and patience I would have never completed this project. i Table of Contents Page Abstract iv Chapter 1: Introduction – why did I choose this subject? 1 The problem and the purpose of the study Chapter 2: Literature Review 5 Introduction - The spectrum of Neuro-behavioral disorders 5 A.